Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800515 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL146546 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL29876183 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL780403 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Bromide SCHEMBL28591637 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL1239204 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Iodide SCHEMBL29040444 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL507110 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL31020152 | 0.85 | IDO1 (0.44) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL659099 | 0.83 | ADRB2 (0.46) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | claimed |
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2015-11-05 | — | — | US | claimed |
| EP-2928860-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2015-10-14 | — | — | EP | claimed |
| WO-2014090731-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-06-19 | — | — | WO | claimed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | claimed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250129041-A1 | MOLECULAR GLUE AND USES THEREOF | ASTROGEN, INC. (KR) | 2025-04-24 | — | — | US | disclosed |
| WO-2025060911-A1 | SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都奥睿药业有限公司 | 2025-03-27 | — | — | WO | disclosed |
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2025-01-02 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | BICRA, C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IDO1 2164/4885TDO2 2207/4885AOC3 3821/4885 |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | IDO1 467/4885TDO2 328/4885AOC3 2597/4885 |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | IDO1 1575/4885TDO2 3009/4885AOC3 1630/4885 |
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | IDO1 3189/4885TDO2 4254/4885AOC3 4072/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | IDO1 362/4885TDO2 262/4885AOC3 111/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | IDO1 1821/4885TDO2 4056/4885AOC3 2626/4885 |
| US-20250129041-A1 | MOLECULAR GLUE AND USES THEREOF | ILK, FGB, UNC119 | IDO1 4688/4885TDO2 4842/4885AOC3 2106/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | IDO1 1102/4885TDO2 2386/4885AOC3 622/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | IDO1 2570/4885TDO2 2789/4885AOC3 2901/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | IDO1 2403/4885TDO2 4532/4885AOC3 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.